Zikou Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Zikou Liu has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Joanne M. Hildebrand
Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
3 shared publications - John Silke
The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
3 shared publications Aleksandra Bankovacki
The Walter and Eliza Hall Institute of Medical Research Parkville VIC Australia
2 shared publicationsCheree Fitzgibbon
The Walter and Eliza Hall Institute of Medical Research Parkville VIC Australia
2 shared publications- David Komander
Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
2 shared publications - James M. Murphy
The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia
2 shared publications
Latest Publications
- 28 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6626-6636
Tenecteplase and other TNK formulations lose PAI-1 resistance in their 2-chain form: comparison with alteplase
Alteplase is synthesized as a single-chain protease that requires plasmin-mediated conversion to its fully active 2-chain form for maximal thrombolysis. Tenecteplase (TNK), an alteplase variant, is widely regarded as being more fibrin selective and more resistant to plasminogen activator inhibitor 1 (PAI-1) than alteplase. However, the PAI-1 sensitivity of TNK after 2-chain conversion and that of newly available TNK formulations has not been evaluated. Alteplase and 4 TNK formulations, Metalyse (Boehringer Ingelheim, Ingelheim am Rheim, Germany), Tenectase (Gennova, Pune, India), GenetPA (BioApower, Jiangsu, Yancheng, China), and Mingfule (CSPC Pharmaceutical Company Ltd, Guangdong, Guangzhou, China) were compared in their native state and after 2-chain conversion. Proteolytic activity and PAI-1 resistance and binding were evaluated using an amidolytic assay, fibrinolysis assays, and western blotting. Alteplase, but not Metalyse, was converted into its 2-chain form in plasma in a fibrinogen-dependent manner, resulting in off-target fibrinogenolysis. When directly reconstituted from the manufacturer’s vial (native form), TNK was approximately fourfold more resistant to PAI-1 than alteplase; however, 2-chain conversion significantly reduced PAI-1 resistance by ∼40%, concomitant with increased PAI-1 binding. Native Metalyse contained approximately threefold more preexisting 2-chain species than the other TNK formulations, explaining its higher amidolytic activity. However, after 2-chain conversion, all TNK formulations showed similar fibrinolytic activity, although with substantially reduced PAI-1 resistance. Metalyse and all new TNK formulations display similar fibrinolytic activity in their fully active 2-chain states, but this is associated with substantial loss of PAI-1 resistance, challenging the view that the fully active 2-chain form of TNK maintains PAI-1 resistance during thrombolysis.
- 28 September 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (19) , 6626-6636
Tenecteplase and other TNK formulations lose PAI-1 resistance in their 2-chain form: comparison with alteplase
Alteplase is synthesized as a single-chain protease that requires plasmin-mediated conversion to its fully active 2-chain form for maximal thrombolysis. Tenecteplase (TNK), an alteplase variant, is widely regarded as being more fibrin selective and more resistant to plasminogen activator inhibitor 1 (PAI-1) than alteplase. However, the PAI-1 sensitivity of TNK after 2-chain conversion and that of newly available TNK formulations has not been evaluated. Alteplase and 4 TNK formulations, Metalyse (Boehringer Ingelheim, Ingelheim am Rheim, Germany), Tenectase (Gennova, Pune, India), GenetPA (BioApower, Jiangsu, Yancheng, China), and Mingfule (CSPC Pharmaceutical Company Ltd, Guangdong, Guangzhou, China) were compared in their native state and after 2-chain conversion. Proteolytic activity and PAI-1 resistance and binding were evaluated using an amidolytic assay, fibrinolysis assays, and western blotting. Alteplase, but not Metalyse, was converted into its 2-chain form in plasma in a fibrinogen-dependent manner, resulting in off-target fibrinogenolysis. When directly reconstituted from the manufacturer’s vial (native form), TNK was approximately fourfold more resistant to PAI-1 than alteplase; however, 2-chain conversion significantly reduced PAI-1 resistance by ∼40%, concomitant with increased PAI-1 binding. Native Metalyse contained approximately threefold more preexisting 2-chain species than the other TNK formulations, explaining its higher amidolytic activity. However, after 2-chain conversion, all TNK formulations showed similar fibrinolytic activity, although with substantially reduced PAI-1 resistance. Metalyse and all new TNK formulations display similar fibrinolytic activity in their fully active 2-chain states, but this is associated with substantial loss of PAI-1 resistance, challenging the view that the fully active 2-chain form of TNK maintains PAI-1 resistance during thrombolysis.
- Open Access
Electrical stimulation of stem cell–derived human neural networks for evaluating anti‐seizure medications
Objective: Current preclinical epilepsy drug screening relies on animal models that poorly reflect human neurophysiology, leading to high failure rates in clinical translation. We aimed to establish a human in vitro model using human‐induced pluripotent stem cell (hiPSC)–derived cortical neurons cultured on multielectrode arrays (MEAs), capable of generating precisely controlled after‐discharges (ADs) through electrical stimulation. We optimized stimulation parameters to evoke epileptiform‐like hypersynchronous events and validated the model using six approved antiseizure medications (ASMs). Methods: hiPSCs were rapidly differentiated into NGN2 cortical neurons and co‐cultured with astrocytes on a 12‐electrode, 24‐well MEA. Network activity was tracked weekly. Upon maturation, biphasic voltage stimuli (400–2000 mV, 10 pulses at 100 Hz, 100 μs phase width) were applied in 100 ms trains to induce ADs. Stimulation intensity was increased until a maximum spike count per burst was reached. The timing of the stimulating inter‐burst interval (IBI) was shortened from 10 to 1 s. We tested six ASMs with distinct mechanisms of action for their ability to attenuate induced ADs, as measured by the area under the curve (AUC) of spikes within bursts. Results: A ±1000 mV stimulus was sufficient to evoke robust ADs; higher voltages caused network instability without enhancing response strength. The maximum hypersynchronous bursting rate was observed with 2 s IBIs, whereas attempts to induce more frequent events using 1 s IBIs led to desynchronization and a reduction in burst frequency below baseline. Phenytoin, perampanel, clonazepam, and lamotrigine significantly reduced AUC within 5 min in a concentration‐dependent manner. Vigabatrin and levetiracetam required longer pre‐incubations: AUC was reduced after 6 h for levetiracetam and at 24 h for vigabatrin. Significance: We present a novel hiPSC‐derived, electrically induced in vitro model for screening ASM candidates. This approach captures human‐relevant epileptiform dynamics, allows fine control over stimulation parameters, and enables testing of diverse drug mechanisms. Its compatibility with high‐throughput platforms makes it a promising tool for ASM discovery and personalized treatment strategies.
Open AccessElectrical stimulation of stem cell–derived human neural networks for evaluating anti‐seizure medications
Objective: Current preclinical epilepsy drug screening relies on animal models that poorly reflect human neurophysiology, leading to high failure rates in clinical translation. We aimed to establish a human in vitro model using human‐induced pluripotent stem cell (hiPSC)–derived cortical neurons cultured on multielectrode arrays (MEAs), capable of generating precisely controlled after‐discharges (ADs) through electrical stimulation. We optimized stimulation parameters to evoke epileptiform‐like hypersynchronous events and validated the model using six approved antiseizure medications (ASMs). Methods: hiPSCs were rapidly differentiated into NGN2 cortical neurons and co‐cultured with astrocytes on a 12‐electrode, 24‐well MEA. Network activity was tracked weekly. Upon maturation, biphasic voltage stimuli (400–2000 mV, 10 pulses at 100 Hz, 100 μs phase width) were applied in 100 ms trains to induce ADs. Stimulation intensity was increased until a maximum spike count per burst was reached. The timing of the stimulating inter‐burst interval (IBI) was shortened from 10 to 1 s. We tested six ASMs with distinct mechanisms of action for their ability to attenuate induced ADs, as measured by the area under the curve (AUC) of spikes within bursts. Results: A ±1000 mV stimulus was sufficient to evoke robust ADs; higher voltages caused network instability without enhancing response strength. The maximum hypersynchronous bursting rate was observed with 2 s IBIs, whereas attempts to induce more frequent events using 1 s IBIs led to desynchronization and a reduction in burst frequency below baseline. Phenytoin, perampanel, clonazepam, and lamotrigine significantly reduced AUC within 5 min in a concentration‐dependent manner. Vigabatrin and levetiracetam required longer pre‐incubations: AUC was reduced after 6 h for levetiracetam and at 24 h for vigabatrin. Significance: We present a novel hiPSC‐derived, electrically induced in vitro model for screening ASM candidates. This approach captures human‐relevant epileptiform dynamics, allows fine control over stimulation parameters, and enables testing of diverse drug mechanisms. Its compatibility with high‐throughput platforms makes it a promising tool for ASM discovery and personalized treatment strategies.
- Open Access
- 27 April 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (4) , 102874
Halo fluorescence fibrinolysis test: a novel quantitative assay to evaluate fibrinolysis on established plasma clots
- 27 April 2025
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 9 (4) , 102874
Open AccessHalo fluorescence fibrinolysis test: a novel quantitative assay to evaluate fibrinolysis on established plasma clots
- 26 October 2021
- Published by Springer Nature in The EMBO Journal
- Vol. 40 (23) , e103718
Oligomerization‐driven MLKL ubiquitylation antagonizes necroptosis
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- 26 October 2021
- Published by Springer Nature in The EMBO Journal
- Vol. 40 (23) , e103718
Oligomerization‐driven MLKL ubiquitylation antagonizes necroptosis
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.
- Open Access
Oligomerization-driven MLKL ubiquitylation antagonises necroptosis
Mixed lineage kinase domain-like (MLKL) is the executioner in the caspase-independent form of programmed cell death called necroptosis. Receptor Interacting serine/threonine Protein Kinase 3 (RIPK3) phosphorylates MLKL, triggering MLKL oligomerization, membrane translocation and membrane disruption. MLKL also undergoes ubiquitylation during necroptosis, yet neither the mechanism nor significance of this event have been demonstrated. Here we show that necroptosis-specific, multi-mono-ubiquitylation of MLKL occurs following its activation and oligomerization. Ubiquitylated MLKL accumulates in a digitonin insoluble cell fraction comprising plasma/organellar membranes and protein aggregates. This ubiquitylated form is diminished by a plasma membrane located deubiquitylating enzyme. MLKL is ubiquitylated on at least 4 separate lysine residues once oligomerized, and this correlates with proteasome- and lysosome-dependent turnover. Using a MLKL-DUB fusion strategy, we show that constitutive removal of ubiquitin from MLKL licences MLKL auto-activity independent of necroptosis signalling in mouse and human cells. Therefore, besides its role in the kinetic regulation of MLKL-induced death following an exogenous necroptotic stimulus, ubiquitylation also contributes to the restraint of basal levels of activated MLKL to avoid errant cell death.
Open AccessOligomerization-driven MLKL ubiquitylation antagonises necroptosis
Mixed lineage kinase domain-like (MLKL) is the executioner in the caspase-independent form of programmed cell death called necroptosis. Receptor Interacting serine/threonine Protein Kinase 3 (RIPK3) phosphorylates MLKL, triggering MLKL oligomerization, membrane translocation and membrane disruption. MLKL also undergoes ubiquitylation during necroptosis, yet neither the mechanism nor significance of this event have been demonstrated. Here we show that necroptosis-specific, multi-mono-ubiquitylation of MLKL occurs following its activation and oligomerization. Ubiquitylated MLKL accumulates in a digitonin insoluble cell fraction comprising plasma/organellar membranes and protein aggregates. This ubiquitylated form is diminished by a plasma membrane located deubiquitylating enzyme. MLKL is ubiquitylated on at least 4 separate lysine residues once oligomerized, and this correlates with proteasome- and lysosome-dependent turnover. Using a MLKL-DUB fusion strategy, we show that constitutive removal of ubiquitin from MLKL licences MLKL auto-activity independent of necroptosis signalling in mouse and human cells. Therefore, besides its role in the kinetic regulation of MLKL-induced death following an exogenous necroptotic stimulus, ubiquitylation also contributes to the restraint of basal levels of activated MLKL to avoid errant cell death.
- Open Access
- 19 June 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-16
A missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction
MLKL is the essential effector of necroptosis, a form of programmed lytic cell death. We have isolated a mouse strain with a single missense mutation,MlklD139V, that alters the two-helix ‘brace’ that connects the killer four-helix bundle and regulatory pseudokinase domains. This confers constitutive, RIPK3 independent killing activity to MLKL. Homozygous mutant mice develop lethal postnatal inflammation of the salivary glands and mediastinum. The normal embryonic development ofMlklD139Vhomozygotes until birth, and the absence of any overt phenotype in heterozygotes provides important in vivo precedent for the capacity of cells to clear activated MLKL. These observations offer an important insight into the potential disease-modulating roles of three common humanMLKLpolymorphisms that encode amino acid substitutions within or adjacent to the brace region. Compound heterozygosity of these variants is found at up to 12-fold the expected frequency in patients that suffer from a pediatric autoinflammatory disease, chronic recurrent multifocal osteomyelitis (CRMO).
- 19 June 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-16
Open AccessA missense mutation in the MLKL brace region promotes lethal neonatal inflammation and hematopoietic dysfunction
MLKL is the essential effector of necroptosis, a form of programmed lytic cell death. We have isolated a mouse strain with a single missense mutation,MlklD139V, that alters the two-helix ‘brace’ that connects the killer four-helix bundle and regulatory pseudokinase domains. This confers constitutive, RIPK3 independent killing activity to MLKL. Homozygous mutant mice develop lethal postnatal inflammation of the salivary glands and mediastinum. The normal embryonic development ofMlklD139Vhomozygotes until birth, and the absence of any overt phenotype in heterozygotes provides important in vivo precedent for the capacity of cells to clear activated MLKL. These observations offer an important insight into the potential disease-modulating roles of three common humanMLKLpolymorphisms that encode amino acid substitutions within or adjacent to the brace region. Compound heterozygosity of these variants is found at up to 12-fold the expected frequency in patients that suffer from a pediatric autoinflammatory disease, chronic recurrent multifocal osteomyelitis (CRMO).
- 1 September 2017
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 331, 69-75
Using DR52c/Ni2+ mimotope tetramers to detect Ni2+ reactive CD4+ T cells in patients with joint replacement failure
- 1 September 2017
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 331, 69-75
Using DR52c/Ni2+ mimotope tetramers to detect Ni2+ reactive CD4+ T cells in patients with joint replacement failure